Literature DB >> 22793854

Biology of human papillomavirus infection and immune therapy for HPV-related head and neck cancers.

Simon R Best1, Kevin J Niparko, Sara I Pai.   

Abstract

This article outlines the biology of human papillomavirus (HPV) infection of human mucosa and the cellular pathways that are altered through viral infection. The article provides a conceptual framework with which to understand the 2 major immunologic strategies to address HPV-related diseases: (1) prevention of primary HPV infection through the use of prophylactic vaccines and (2) treatment of established infection and diseases through therapeutic vaccines. Nonimmunologic therapy that targets cellular dysregulation induced by HPV infection is also discussed. The challenges in actualizing these conceptually attractive therapies on both a societal and biological level are examined.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22793854      PMCID： PMC3398423          DOI： 10.1016/j.otc.2012.04.005

Source DB:  PubMed          Journal:  Otolaryngol Clin North Am        ISSN： 0030-6665            Impact factor:   3.346


  70 in total

1.  Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes.

Authors:  M Nees; J M Geoghegan; T Hyman; S Frank; L Miller; C D Woodworth
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

Review 2.  Immune evasion in human papillomavirus-associated cervical cancer.

Authors:  Robert W Tindle
Journal:  Nat Rev Cancer       Date:  2002-01       Impact factor: 60.716

3.  Integrated human papillomavirus type 16 is frequently found in cervical cancer precursors as demonstrated by a novel quantitative real-time PCR technique.

Authors:  Panu Peitsaro; Bo Johansson; Stina Syrjänen
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

4.  Both E6 and E7 oncoproteins of human papillomavirus 16 inhibit IL-18-induced IFN-gamma production in human peripheral blood mononuclear and NK cells.

Authors:  S J Lee; Y S Cho; M C Cho; J H Shim; K A Lee; K K Ko; Y K Choe; S N Park; T Hoshino; S Kim; C A Dinarello; D Y Yoon
Journal:  J Immunol       Date:  2001-07-01       Impact factor: 5.422

5.  Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen.

Authors:  W F Cheng; C F Hung; C Y Chai; K F Hsu; L He; M Ling; T C Wu
Journal:  J Clin Invest       Date:  2001-09       Impact factor: 14.808

6.  Antibodies against the human papillomavirus type 16 early proteins in human sera: correlation of anti-E7 reactivity with cervical cancer.

Authors:  I Jochmus-Kudielka; A Schneider; R Braun; R Kimmig; U Koldovsky; K E Schneweis; K Seedorf; L Gissmann
Journal:  J Natl Cancer Inst       Date:  1989-11-15       Impact factor: 13.506

7.  Down regulation of the interleukin-8 promoter by human papillomavirus type 16 E6 and E7 through effects on CREB binding protein/p300 and P/CAF.

Authors:  Shih-Min Huang; D J McCance
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

8.  Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles.

Authors:  J Zhou; X Y Sun; D J Stenzel; I H Frazer
Journal:  Virology       Date:  1991-11       Impact factor: 3.616

Review 9.  Role of the human papillomaviruses in human cancer.

Authors:  P M Howley
Journal:  Cancer Res       Date:  1991-09-15       Impact factor: 12.701

10.  Human papillomavirus type 16 E5 gene stimulates the transforming activity of the epidermal growth factor receptor.

Authors:  D Pim; M Collins; L Banks
Journal:  Oncogene       Date:  1992-01       Impact factor: 9.867
View more
  15 in total

1.  Immune Modulation and Treatment of Human Papilloma Virus-Related Warts with Energetics of Living Systems Acupuncture.

Authors:  Rom Brustin; Martine Toledano; Tal Geffen; Raia Goona; Malka Hochberg; Bilha Kreisberg; Sari Murad; Jacob Pitcovski
Journal:  Med Acupunct       Date:  2017-06-01

2.  Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine.

Authors:  Ricardo Rosales; Mario López-Contreras; Carlos Rosales; Jose-Roberto Magallanes-Molina; Roberto Gonzalez-Vergara; Jose Martin Arroyo-Cazarez; Antonio Ricardez-Arenas; Armando Del Follo-Valencia; Santiago Padilla-Arriaga; Miriam Veronica Guerrero; Miguel Angel Pirez; Claudia Arellano-Fiore; Freddy Villarreal
Journal:  Hum Gene Ther       Date:  2014-12       Impact factor: 5.695

3.  Immunometabolic Alterations by HPV Infection: New Dimensions to Head and Neck Cancer Disparity.

Authors:  Sanjib Chaudhary; Koelina Ganguly; Sakthivel Muniyan; Ramesh Pothuraju; Zafar Sayed; Dwight T Jones; Surinder K Batra; Muzafar A Macha
Journal:  J Natl Cancer Inst       Date:  2019-03-01       Impact factor: 13.506

Review 4.  Immune therapy for human papillomaviruses-related cancers.

Authors:  Ricardo Rosales; Carlos Rosales
Journal:  World J Clin Oncol       Date:  2014-12-10

5.  Association of serum cytokines with oral HPV clearance.

Authors:  Jennifer O Lam; Jay H Bream; Elizabeth A Sugar; Christian L Coles; Kathleen M Weber; Robert D Burk; Dorothy J Wiley; Ross D Cranston; Susheel Reddy; Joseph B Margolick; Howard D Strickler; Alicia Wentz; Lisa Jacobson; Yingshi Guo; Weihong Xiao; Maura L Gillison; Gypsyamber D'Souza
Journal:  Cytokine       Date:  2016-04-08       Impact factor: 3.861

6.  Serum Adenosine Deaminase Levels and Human Papillomavirus as Prognostic and Predictive Factors for Laryngeal and Pharyngeal Carcinomas.

Authors:  C Chandrakiran; Thanu Jogy; Sanjay B Patil
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2018-04-30

Review 7.  Recent Progress in Therapeutic Treatments and Screening Strategies for the Prevention and Treatment of HPV-Associated Head and Neck Cancer.

Authors:  Sonia N Whang; Maria Filippova; Penelope Duerksen-Hughes
Journal:  Viruses       Date:  2015-09-17       Impact factor: 5.048

8.  Human immunodeficiency virus is a driven factor of human papilloma virus among women: evidence from a cross-sectional analysis in Yaoundé, Cameroon.

Authors:  Samuel Martin Sosso; Michel Carlos Tommo Tchouaket; Joseph Fokam; Rachel Kamgaing Simo; Judith Torimiro; Aline Tiga; Elise Elong Lobe; Georgia Ambada; Achille Nange; Ezechiel Ngoufack Jagni Semengue; Alex Durand Nka; Valère Tala; Collins Chenwi; Aissatou Abba; Aude Christelle Ka'e; Bouba Yagai; Vittorio Colizzi; Alexis Ndjolo
Journal:  Virol J       Date:  2020-05-19       Impact factor: 4.099

Review 9.  The immune system and head and neck squamous cell carcinoma: from carcinogenesis to new therapeutic opportunities.

Authors:  Monika E Freiser; Paolo Serafini; Donald T Weed
Journal:  Immunol Res       Date:  2013-12       Impact factor: 4.505

10.  Combined STING levels and CD103+ T cell infiltration have significant prognostic implications for patients with cervical cancer.

Authors:  Arjan Kol; Joyce M Lubbers; Anouk L J Terwindt; Hagma H Workel; Annechien Plat; G Bea A Wisman; Joost Bart; Hans W Nijman; Marco De Bruyn
Journal:  Oncoimmunology       Date:  2021-06-12       Impact factor: 8.110
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.